ArticleOncotarget2017
Real-time
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- Review
- Open-field fluorescence guided imaging of ameloblastoma tumors in mouse patient-derived xenograft model.BMC oral health · 2026Article
- How the bone microenvironment shapes the pre-metastatic niche and metastasis.Nature cancer · 2024Review
- Tissue-seeking dyes for in vivo applications.Smart molecules : open access · 2024Review
- P800SO3-PEG: a renal clearable bone-targeted fluorophore for theranostic imaging.Biomaterials research · 2022Article
- Precise Diagnosis and Therapy of Bone Cancer Using Near-Infrared Lights.Frontiers in bioengineering and biotechnology · 2021Review
- Comparison of photoacoustic and fluorescence tomography for thePhotoacoustics · 2020Article
- Fluorescently Labeled Cetuximab-IRDye800 for Guided Surgical Excision of Ameloblastoma: A Proof of Principle Study.Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons · 2020Article
- Bioluminescence and near-infrared fluorescence imaging for detection of metastatic bone tumors.Lasers in medical science · 2020Article
- Near-Infrared Contrast Agents for Bone-Targeted Imaging.Tissue engineering and regenerative medicine · 2019Review
- Targeted imaging and inhibition of triple-negative breast cancer metastases by a PDGFRβ aptamer.Theranostics · 2018Article
- Low-Dose Evans Blue Dye for Near-Infrared Fluorescence Imaging in Photothrombotic Stroke Model.International journal of medical sciences · 2018Article
- Real-Time Tracking ofFrontiers in immunology · 2018Article
- ZW800-1 for Assessment of Blood-Brain Barrier Disruption in a Photothrombotic Stroke Model.International journal of medical sciences · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumors of the prostate or breast are particularly likely to metastasize to the bone, and early diagnosis of metastatic bone tumors is important for designing an effective treatment strategy. Imaging modalities for the detection of bone metastasis are limited, and radiation-based techniques are commonly used. Here, we investigated the efficacy of selective near-infrared (NIR) fluorescence detection of metastatic bone tumors and its role in the detection of bone metastasis in prostate and breast cancer cell lines and in a xenograft mouse model. A targeted NIR fluorophore was used to monitor metastatic bone tumors using a NIR fluorescence imaging system in real time, enabling the diagnosis of bone metastasis
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.